Bone metastatic cancer of unknown primary at initial presentation

• Masatake Matsuoka ^[1] ; Tomohiro Onodera ^[1] ; Isao Yokota ^[2] ; Koji Iwasaki ^[3] ; Yuki Suzuki ^[1] ; Hamasaki Masanari ^[1] ; Eiji Kondo ^[4] ; Norimasa Iwasaki ^[1]
  1. [1] Department of Orthopaedic Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Japan
  2. [2] Department of Biostatistics, Graduate School of Medicine, Hokkaido University, Japan
  3. [3] Department of Functional Reconstruction for the Knee Joint, Hokkaido University, Japan
  4. [4] Centre for Sports Medicine, Hokkaido University Hospital, Japan

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 26, Nº. 2, 2024, págs. 461-467
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Introduction Cancer of unknown primary (CUP) is a challenging malignancy. The purpose of this study was to investigate the clinical characteristics and prognosis of bone metastatic CUP using the population-based Surveillance, Epidemiology, and End Results (SEER) database.

    Methods From the SEER database, we identified 1908 patients with bone metastatic CUP at initial presentation between 2010 and 2018. Histology was subdivided following International Classification of Diseases for Oncology codes as Adenocarcinoma, Squamous cell, Neuroendocrine, or Carcinoma not otherwise specified (NOS). Cox proportional hazard modeling was applied using factors of age, sex, ethnicity, histological subtype, and therapeutic intervention.

    Results Among the 1908 patients, histology was Neuroendocrine in 240 patients, Squamous cell in 201 patients, Adenocarcinoma in 810 patients and NOS in 657 patients. In each subtype, patients tended to be predominantly male and white. Chemotherapy was introduced for 28% of patients and radiation for 34% in the entire cohort. Survival in patients with bone metastatic CUP was unfavorable, with a median survival of 2 months. Among the histological subtypes, Adenocarcinoma showed shorter survival than the other groups. In addition, treatment interventions such as chemotherapy and radiation therapy prolonged survival, particularly for Squamous cell, Adenocarcinoma and NOS, but not for Neuroendocrine.

    Discussion Bone metastatic CUP showed extremely poor prognosis, but treatment interventions such as chemotherapy and radiation generally offered survival benefits. Further randomized clinical research is needed to confirm the present results.